Date | Price Target | Rating | Analyst |
---|---|---|---|
9/17/2024 | $55.00 → $66.00 | Neutral → Outperform | Robert W. Baird |
3/20/2024 | Buy | Needham | |
2/20/2024 | $60.00 → $70.00 | Neutral → Buy | Mizuho |
9/6/2023 | $52.00 | Hold | HSBC Securities |
7/19/2023 | $56.00 | Neutral | Robert W. Baird |
4/14/2023 | $48.00 | Neutral | Mizuho |
12/21/2022 | $62.00 | Equal Weight | Barclays |
4/6/2022 | $95.00 | Outperform | Wolfe Research |
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights(1) Second-quarter revenue of $318.6 million increased 8.4% on a reported basis and 9.6% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 10.8% on a constant-currency basis. Second-quarter U.S. GAAP diluted earnings per share of $0.30 and adjusted diluted earnings per share of $0.93. Franco Poletti named President of Ca
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2024 results on Wednesday, July 31, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its second-quarter 2024 results prior to the call. A live audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 926038. A replay will be available on t
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights(1) First-quarter revenue of $294.9 million increased 12.0% on a reported basis and 12.4% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 13.5% on a constant-currency basis First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73 Closed private offering of $345.0 milli
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Baird 2024 Global Healthcare Conference in New York. The presentation will take place at 10:15 a.m. Eastern Time on Tuesday, September 10. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the webcast. A replay will be available on the LivaNova website within 24 hours after the live presentation for 90 days after the event. About L
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights(1) Second-quarter revenue of $318.6 million increased 8.4% on a reported basis and 9.6% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 10.8% on a constant-currency basis. Second-quarter U.S. GAAP diluted earnings per share of $0.30 and adjusted diluted earnings per share of $0.93. Franco Poletti named President of Ca
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2024 results on Wednesday, July 31, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its second-quarter 2024 results prior to the call. A live audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 926038. A replay will be available on t
Stifel analyst Rick Wise maintains LivaNova (NASDAQ:LIVN) with a Buy and raises the price target from $70 to $72.
Shares of G-III Apparel Group, Ltd. (NASDAQ:GIII) fell sharply during Thursday's session after the company reported worse-than-expected quarterly sales results. G-III Apparel Group posted adjusted earnings of 13 cents per share, according to data from Benzinga Pro. The company's quarterly sales came in at $609.747 million, missing market estimates of $616.286 million. G-III Apparel Group shares dipped 13.4% to $27.12 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Virax Biolabs Group Limited (NASDAQ:VRAX) shares jumped 139.4% to $2.5390. American Oncology Network, Inc. (NASDAQ:AONC) gained 102% to $4.52. American Oncology Network expanded
Needham analyst Mike Matson reiterates LivaNova (NASDAQ:LIVN) with a Buy and maintains $72 price target.
SC 13G - LivaNova PLC (0001639691) (Subject)
SC 13G/A - LivaNova PLC (0001639691) (Subject)
SC 13G/A - LivaNova PLC (0001639691) (Subject)
8-K - LivaNova PLC (0001639691) (Filer)
IRANNOTICE - LivaNova PLC (0001639691) (Filer)
10-Q - LivaNova PLC (0001639691) (Filer)
Robert W. Baird upgraded LivaNova from Neutral to Outperform and set a new price target of $66.00 from $55.00 previously
Needham reiterated coverage of LivaNova with a rating of Buy
Mizuho upgraded LivaNova from Neutral to Buy and set a new price target of $70.00 from $60.00 previously
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024. In this newly created position, Tezel will leverage his career of more than 20 years in research and development (R&D) to establish an integrated innovation function at LivaNova that will accelerate the Company's development of new technologies. In this capacity, Tezel will join the LivaNova Executive Leadership Team. "I am very pleased to welcome Ahmet to the LivaNova team. At LivaNova, our commitment to pioneering innovation remains unwavering, and Ahmet's arrival marks a significant step in advanci
Long-time Director Andrea Saia to retire from the Board LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today. Barry will serve on the Audit and Compliance Committee. Andrea Saia, who has served as a Director since 2016, will retire from the LivaNova Board on December 31, 2023. "The LivaNova Board of Directors is pleased to welcome Chris Barry," said Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova. "Chris has spent his career in the medical technology industry, and we look forward to adding his commercial expertise and ability to drive long-term gro
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Marco Dolci intends to retire as President of the Cardiopulmonary (CP) Business Unit (BU) by December 31, 2023. Dolci will continue in his role and support the transition of responsibilities through the end of the year. Franco Poletti will serve as Interim General Manager of CP to support the transition efforts, in addition to his current role as Vice President of CP for Europe, effective immediately. LivaNova will retain a leading international executive search firm to assist with the search for a permanent successor for the President of CP. "On behalf of the Board, the executive leadership team
4 - LivaNova PLC (0001639691) (Issuer)
3/A - LivaNova PLC (0001639691) (Issuer)
4 - LivaNova PLC (0001639691) (Issuer)